VIKAS KUMAR SINGH
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology LOUISVILLE, KY NPI 1124375134
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology KY EISAI INC. All categories
General Payments — all program years on this page
$25,153.73
- Category: General Payments
- Program years: PY2018–2024
- Record count: 301
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $3,636.46 across 53 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,535.00 | 2 |
| Food and Beverage | $1,101.46 | 51 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| EISAI INC. | $2,010.00 | 1 |
| Acerta Pharma LLC | $639.14 | 7 |
| Genmab U.S., Inc. | $158.58 | 3 |
| PFIZER INC. | $99.02 | 6 |
| JAZZ PHARMACEUTICALS INC. | $64.29 | 2 |
| Tempus AI, Inc | $60.09 | 2 |
| SOBI, INC | $59.52 | 3 |
| Genentech USA, Inc. | $58.08 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $45.63 | 3 |
| Regeneron Healthcare Solutions, Inc. | $39.83 | 2 |
| Incyte Corporation | $39.81 | 2 |
| Janssen Biotech, Inc. | $38.42 | 1 |
| ABBVIE INC. | $33.79 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $31.45 | 2 |
| TerSera Therapeutics LLC | $27.36 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.10 | 1 |
| Astellas Pharma US Inc | $20.60 | 1 |
| Sumitomo Pharma America, Inc. | $20.44 | 1 |
| Gilead Sciences, Inc. | $20.16 | 1 |
| Stemline Therapeutics Inc. | $19.29 | 1 |
| AngioDynamics, Inc. | $17.31 | 1 |
| ARRAY BIOPHARMA INC | $15.59 | 1 |
| Pharmacosmos Therapeutics Inc. | $15.57 | 1 |
| Novocure Inc. | $15.39 | 1 |
| SpringWorks Therapeutics, Inc. | $14.52 | 1 |
| SERVIER PHARMACEUTICALS LLC | $14.24 | 1 |
| Daiichi Sankyo Inc. | $14.12 | 1 |
| Fennec Pharmaceuticals, Inc. | $13.12 | 1 |
| Rigel Pharmaceuticals, Inc. | $5.00 | 1 |
By program year
Records — PY2024 (53)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.